BGB324, our first-in-class selective AXL kinase inhibitor, is currently in large-scale Phase 2 clinical testing in North America and Europe. Study investigators are recruiting patients with AML as well as NSCLC and welcome enquiries from potential participants.
If you, or a loved one, are at least 18 years old and are diagnosed with AML and want to learn more about our study please use the following link: Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With AML.
If you, or a loved one, are at least 18 years old and are diagnosed with stage IV NSCLC and want to learn about our lung cancer trial please follow this link: A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer.
Further Phase 2 studies of BGB324 in combination with Pembrolizumab, a PD-1 immune checkpoint inhibitor, in patients with adenocarcinoma of the lung and triple negative breast cancer are expected to commence during 2017 and are conducted in collaboration with Merck.
Study investigators welcome enquiries from potential participants.